193 related articles for article (PubMed ID: 33245181)
1. A review of the experience with pediatric written requests issued for oncology drug products.
Akalu AY; Meng X; Reaman GH; Ma L; Yuan W; Ye J
Pediatr Blood Cancer; 2021 Feb; 68(2):e28828. PubMed ID: 33245181
[TBL] [Abstract][Full Text] [Related]
2. The impact of the written request process on drug development in childhood cancer.
Snyder KM; Reaman G; Avant D; Pazdur R
Pediatr Blood Cancer; 2013 Apr; 60(4):531-7. PubMed ID: 23335552
[TBL] [Abstract][Full Text] [Related]
3. Review of Racial and Ethnic Representation of Participants Enrolled in Pediatric Clinical Trials of Oncology Drugs Conducted Through FDA Written Requests.
Fashoyin-Aje LA; Akalu AY; Boehmer J; Pazdur R; Donoghue M; Reaman GH
JAMA Oncol; 2024 Mar; 10(3):380-383. PubMed ID: 38175622
[TBL] [Abstract][Full Text] [Related]
4. Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy.
Wharton GT; Murphy MD; Avant D; Goldsmith JV; Chai G; Rodriguez WJ; Eisenstein EL
Pediatrics; 2014 Aug; 134(2):e512-8. PubMed ID: 25022732
[TBL] [Abstract][Full Text] [Related]
5. Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018.
Tanaudommongkon I; John Miyagi S; Green DJ; Burnham JM; van den Anker JN; Park K; Wu J; McCune SK; Yao L; Burckart GJ
Clin Pharmacol Ther; 2020 Nov; 108(5):1018-1025. PubMed ID: 32394430
[TBL] [Abstract][Full Text] [Related]
6. Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities.
Barone A; Casey D; McKee AE; Reaman G
Pediatr Blood Cancer; 2019 Aug; 66(8):e27809. PubMed ID: 31144772
[TBL] [Abstract][Full Text] [Related]
7. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
[TBL] [Abstract][Full Text] [Related]
8. The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs.
Zettler ME
Expert Rev Anticancer Ther; 2022 Mar; 22(3):317-321. PubMed ID: 35051348
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial considerations for pediatric cancer drug development.
Cooner F; Ye J; Reaman G
J Biopharm Stat; 2023 Nov; 33(6):859-874. PubMed ID: 36749066
[TBL] [Abstract][Full Text] [Related]
10. Pediatric Drug Policies Supporting Safe And Effective Use Of Therapeutics In Children: A Systematic Analysis.
Carmack M; Hwang T; Bourgeois FT
Health Aff (Millwood); 2020 Oct; 39(10):1799-1805. PubMed ID: 33017255
[TBL] [Abstract][Full Text] [Related]
11. Dermatology Drugs for Children-U.S. Food and Drug Administration Perspective.
Epps RE
Dermatol Clin; 2022 Jul; 40(3):289-296. PubMed ID: 35750412
[TBL] [Abstract][Full Text] [Related]
12. Regulatory Approval Scenario of Biosimilars in Pediatric Patients in the United States and European Union.
Radhakrishna S; Dahiya M; Pipalava P; Jose V
Pharmaceut Med; 2021 Mar; 35(2):93-112. PubMed ID: 33595810
[TBL] [Abstract][Full Text] [Related]
13. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
14. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
[TBL] [Abstract][Full Text] [Related]
15. IOM Review of FDA--approved biologics labeled or studied for pediatric use.
Field MJ; Ellinger LK; Boat TF
Pediatrics; 2013 Feb; 131(2):328-35. PubMed ID: 23319521
[TBL] [Abstract][Full Text] [Related]
16. Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis.
Hudgins JD; Bacho MA; Olsen KL; Bourgeois FT
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):161-167. PubMed ID: 29148107
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.
Rioux N; Waters NJ
Drug Metab Dispos; 2016 Jul; 44(7):934-43. PubMed ID: 26936973
[TBL] [Abstract][Full Text] [Related]
18. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers.
Hwang TJ; Orenstein L; DuBois SG; Janeway KA; Bourgeois FT
J Natl Cancer Inst; 2020 Mar; 112(3):224-228. PubMed ID: 31665394
[TBL] [Abstract][Full Text] [Related]
19. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
20. FDA update.
Katz R
Epilepsy Res; 2006 Jan; 68(1):85-94. PubMed ID: 16377143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
